David Fellows is the founder of Beacon Therapeutics. Beacon Therapeutics has raised $290M in total funding. Latest round: Series B. Based in London, England.
David Fellows is the CEO of Beacon Therapeutics, an ophthalmic gene therapy company focused on saving and restoring the vision of patients with blinding retinal diseases. The company recently raised $170 million in Series B funding, bringing its total funding to approximately $290 million. Beacon Therapeutics is advancing its lead asset, AGTC-501, for X-Linked Retinitis Pigmentosa, and has a broader pipeline of ophthalmic gene therapies.
Full founder directory · Investor directory · Company funding database · Fundraising library